New cell therapy trial aims to tame lupus and scleroderma

NCT ID NCT06434363

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times

Summary

This study tests a new treatment for people with autoimmune disorders like systemic sclerosis, lupus, and lupus nephritis. It combines a special immune cell therapy (AD-PluReceptor-NK cells) with a drug called tafasitamab and chemotherapy. The goal is to find a safe dose and see if it can help control the disease. About 47 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The University of Texas Health Science Center at Houston

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.